Bosutinib

Bosutinib

CAT N°: 12030
Price:

From 66.00 56.10

Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively).{22602,22595} It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others.{22603} Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM.{22602} It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.{22595}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
  • Correlated keywords
    • inhibitors cancers signals transduction potent dual inhibits inhibitions c-Src Abl cSrc regulating regulates tumors growth differentiation nanomolar SRC TEC Yes Fgr Lck Fyn kinases SKI606 SKI 606 SKIs SKI-606
  • Product Overview:
    Bosutinib is an inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively).{22602,22595} It also inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others.{22603} Bosutinib inhibits Src-dependent cell proliferation (IC50 = 100 nM) and reverses Src-transformed fibroblasts to a non-transformed morphology when used at a concentration of 1 µM.{22602} It reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models when administered at doses of 30 or 25 mg/kg, respectively, twice per day. Bosutinib (100 mg/kg) also induces complete tumor regression in a K562 mouse xenograft model when administered once per day for five days.{22595}

We also advise you